Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Orchard Therapeutics

    Client Virtual Booth

    ORCHARD THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Orchard Therapeutics
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    108 Cannon Street London EC4N 6EU
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.orchard-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orchard-therapeutics/?originalSubdomain=in
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Kyowa's Orchard hopes $4.25M gene therapy price tag bears fruit
    Kyowa's Orchard hopes $4.25M gene therapy price tag bears fruit

    https://www.fiercepharma.com/pharma/kyowa-kirins-orchard-sets-new-gene-therapy-price-tag-425m-steepest-any-drug-us

    Fraiser Kansteiner FIERCE PHARMA
    20 Mar 2024
    Share Share
    US approves first gene therapy for children with rare genetic disease
    US approves first gene therapy for children with rare genetic disease

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-first-gene-therapy-rare-genetic-disease-2024-03-18/

    REUTERS
    19 Mar 2024
    Share Share
    Orchard Therapeutics Receives FDA Approval of Lenmeldy(atidarsagene autotemcel),
    Orchard Therapeutics Receives FDA Approval of Lenmeldy(atidarsagene autotemcel),

    https://www.globenewswire.com/news-release/2024/03/18/2848132/0/en/Orchard-Therapeutics-Receives-FDA-Approval-of-Lenmeldy-atidarsagene-autotemcel-the-Only-Therapy-for-Eligible-Children-with-Early-onset-Metachromatic-Leukodystrophy-in-the-U-S.html

    GLOBENEWSWIRE
    18 Mar 2024
    Share Share
    Orchard Announces First Patient Randomized in Registrational Trial of OTL-203
    Orchard Announces First Patient Randomized in Registrational Trial of OTL-203

    https://www.globenewswire.com//news-release/2024/02/05/2823377/0/en/Orchard-Therapeutics-Announces-First-Patient-Randomized-in-Registrational-Trial-of-OTL-203-for-MPS-I-Hurler-Syndrome.html

    GLOBENEWSWIRE
    05 Feb 2024
    Share Share
    Orchard Therapeutics Announces Agreement with the Beneluxa Consortium
    Orchard Therapeutics Announces Agreement with the Beneluxa Consortium

    https://www.globenewswire.com//news-release/2024/01/25/2816563/0/en/Orchard-Therapeutics-Announces-Agreement-with-the-Beneluxa-Consortium-Enabling-Reimbursed-Access-to-Libmeldy.html

    GLOBENEWSWIRE
    25 Jan 2024
    Share Share
    Kyowa Kirin successfully completes acquisition of Orchard Therapeutics
    Kyowa Kirin successfully completes acquisition of Orchard Therapeutics

    https://www.globenewswire.com//news-release/2024/01/24/2814887/0/en/Kyowa-Kirin-successfully-completes-acquisition-of-Orchard-Therapeutics-a-global-gene-therapy-leader-for-rare-diseases.html

    GLOBENEWSWIRE
    24 Jan 2024
    Share Share
    Orchard Receives Swissmedic Approval for Libmeldy in Early-onset MLD
    Orchard Receives Swissmedic Approval for Libmeldy in Early-onset MLD

    https://www.globenewswire.com//news-release/2023/12/11/2793712/0/en/Orchard-Therapeutics-Receives-Swissmedic-Approval-for-Libmeldy-in-Early-onset-MLD.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share
    Orchard Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
    Orchard Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

    https://www.globenewswire.com//news-release/2023/11/30/2788476/0/en/Orchard-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-OTL-203-in-MPS-IH.html

    GLOBENEWSWIRE
    30 Nov 2023
    Share Share
    Orchard Announces Presentation of Additional Positive Data from OTL-203
    Orchard Announces Presentation of Additional Positive Data from OTL-203

    https://www.globenewswire.com//news-release/2023/10/26/2767345/0/en/Orchard-Therapeutics-Announces-Presentation-of-Additional-Positive-Data-from-Proof-of-concept-Study-of-OTL-203-in-MPS-IH-at-ESGCT-2023.html

    GLOBENEWSWIRE
    26 Oct 2023
    Share Share
    Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
    Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

    https://www.globenewswire.com//news-release/2023/10/24/2765468/0/en/Orchard-Therapeutics-Announces-Multiple-Presentations-at-ESGCT-2023.html

    GLOBENEWSWIRE
    24 Oct 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search